- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05201781
Une étude à long terme pour les participants précédemment traités avec Ciltacabtagene Autoleucel
Étude de suivi à long terme pour les participants précédemment traités avec le ciltacabtagene autoleucel
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Aperçu de l'étude
Description détaillée
Cilta-cel (JNJ-68284528/LCAR-B38M chimeric antigen receptor T-cells [CAR-T]) is an autologous CAR-T therapy that targets B-cell maturation antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. There will be no treatment administered during the study and the data obtained from this study will help to assess whether there will be long-term cilta-cel-related toxicities. The study will consist of 2 phases: within the first 5 years after receiving the last dose of cilta-cel and Year 6 to 15 years after last dose of cilta-cel. Safety evaluations will include a review of adverse events, laboratory test results, and physical examination findings (including neurological examination). The duration of the study is up to 15 years after last dose of cilta-cel and participants will be followed at least once per year.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Accès étendu
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Contact
- Numéro de téléphone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lieux d'étude
-
-
-
Ghent, Belgique, 9000
- Recrutement
- UZ Gent
-
Leuven, Belgique, 3000
- Recrutement
- UZ Leuven
-
-
-
-
-
Beijing, Chine, 100191
- Actif, ne recrute pas
- Peking University Third Hospital
-
Chengdu, Chine, 610041
- Actif, ne recrute pas
- West China Hospital Si Chuan University
-
Fuzhou, Chine, 350000
- Actif, ne recrute pas
- Fujian Medical University Union Hospital
-
Guangzhou, Chine, 510060
- Actif, ne recrute pas
- Sun Yat-sen University Cancer Hospital
-
Hangzhou, Chine, 310003
- Actif, ne recrute pas
- First Hospital, Zhejiang University Medical College
-
Nanjing, Chine, 210008
- Actif, ne recrute pas
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
Nanjing, Chine, 210029
- Actif, ne recrute pas
- Jiangsu Province Hospital
-
Shanghai, Chine, 200003
- Actif, ne recrute pas
- Shanghai Changzheng Hospital
-
Shanghai, Chine, 200434
- Actif, ne recrute pas
- Shanghai Fourth People s Hospital
-
Shanghai, Chine, 200025
- Actif, ne recrute pas
- Ruijin Hospital Shanghai Jiao Tong University
-
Xi'an, Chine, 710004
- Actif, ne recrute pas
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
-
-
-
-
Pamplona, Espagne, 31008
- Recrutement
- Clinica Univ. de Navarra
-
Salamanca, Espagne, 37007
- Recrutement
- Hosp Clinico Univ de Salamanca
-
-
-
-
-
Nord, France, 59037
- Recrutement
- CHRU de Lille Hopital Claude Huriez
-
Paris, France, 75010
- Recrutement
- Hopital Saint Louis
-
-
-
-
-
Tel Aviv, Israël, 64239
- Recrutement
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Nagoya, Japon, 467 8602
- Actif, ne recrute pas
- Nagoya City University Hospital
-
Shibuya City, Japon, 150-8935
- Actif, ne recrute pas
- Japanese Red Cross Medical Center
-
-
-
-
-
Amsterdam, Pays-Bas, 1081 HV
- Recrutement
- VU Medisch Centrum
-
Groningen, Pays-Bas, 9713 GZ
- Recrutement
- University Medical Center Groningen
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Recrutement
- Mayo Clinic Cancer Center-Scottsdale
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- City of Hope
-
San Francisco, California, États-Unis, 94143
- Recrutement
- University of California San Francisco
-
Stanford, California, États-Unis, 94305-5623
- Recrutement
- Stanford University Medical Center
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
Chicago, Illinois, États-Unis, 60611
- Recrutement
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University
-
-
Kansas
-
Westwood, Kansas, États-Unis, 66205
- Recrutement
- Kansas University Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Dana Farber Cancer Institute
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Recrutement
- Barbara Ann Karmanos Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55902
- Recrutement
- Mayo Clinic Rochester
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University School Of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Recrutement
- Hackensack University Medical Center
-
New Brunswick, New Jersey, États-Unis, 08903
- Recrutement
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Buffalo, New York, États-Unis, 14263
- Recrutement
- Roswell Park Cancer Institute
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center
-
New York, New York, États-Unis, 10029
- Recrutement
- Mount Sinai Medical Center
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Recrutement
- Levine Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Recrutement
- University of Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- Recrutement
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Sarah Cannon Research Institute
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- Froedtert Memorial
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- Participants who have provided informed consent for this study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cilta-cel
Participants who had previously received treatment with cilta-cel in a Company-sponsored clinical study (example, NCT04923893, NCT03758417, NCT04181827, NCT05347485, NCT04133636, and NCT03548207) in the global development program will be enrolled into this study once the individual's participation in the particular interventional study has ended or a study has been terminated. Participants will not receive any treatment in this study and will be followed-up at least once per year on delayed adverse events for up to 15 years after receiving the last dose of cilta-cel. |
Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy
Délai: Up to 15 years
|
Number of participants with new malignancies and recurrence of pre-existing malignancy will be reported. |
Up to 15 years
|
|
Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder
Délai: Up to 15 years
|
Number of participants with new incidence or exacerbation of a pre-existing neurologic disorder will be reported. |
Up to 15 years
|
|
Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune Disorder
Délai: Up to 15 years
|
Number of participants with new incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder will be reported. |
Up to 15 years
|
|
Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including Hypogammaglobulinemia
Délai: From year 1 up to year 5
|
Number of participants with new incidence of Grade >=3 hematologic disorder including hypogammaglobulinemia will be reported. |
From year 1 up to year 5
|
|
Number of Participants with Serious Hematologic Disorder, including Hypogammaglobulinemia
Délai: From year 6 up to year 15
|
Number of participants with serious hematologic disorder, including hypogammaglobulinemia will be reported. Serious hematologic disorder, includes hypogammaglobulinemia (all grades, regardless of causality). |
From year 6 up to year 15
|
|
Number of Participants with New Incidence of Grade >= 3 Infection
Délai: From year 1 up to year 5
|
Number of participants with new incidence of Grade >=3 infection will be reported. |
From year 1 up to year 5
|
|
Number of Participants with Serious Infection
Délai: From year 6 up to year 15
|
Number of participants with serious infection will be reported. Serious infection includes all grades, regardless of causality. |
From year 6 up to year 15
|
|
Number of Participants with Serious Adverse Events (SAEs)
Délai: From year 1 up to year 5
|
A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
From year 1 up to year 5
|
|
Number of Participants with Related Serious Adverse Events Assessed by the Investigator
Délai: From year 6 up to year 15
|
Number of participants with related serious adverse events assessed by the investigator will be reported. A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important. |
From year 6 up to year 15
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Peripheral Blood
Délai: Up to 15 years
|
Number of participants with measurable RCL in peripheral blood will be reported. |
Up to 15 years
|
|
Number of Participants with Chimeric Antigen Receptor (CAR) Transgene Level Greater Than (>) Lower Limit of Quantitation (LLOQ) in Peripheral Blood Cells
Délai: Up to 15 years
|
Number of participants with CAR transgene level >LLOQ in peripheral blood cells will be reported. |
Up to 15 years
|
|
Pattern of Lentiviral Vector Integration Sites
Délai: Up to 15 years
|
Pattern of lentiviral vector integration sites if at least 1 percent (%) of cells in the blood sample or new malignancy are positive for vector sequences will be reported. |
Up to 15 years
|
|
Investigator's Response Assessment of Long Term Follow-up on Chimeric Antigen Receptor T-cell (CAR-T) Therapy Based on Local Lab Assessments
Délai: Up to 15 years
|
Investigator's response assessment of long term follow-up on CAR-T therapy based on local lab assessments if the participant does not have confirmed disease progression or does not initiate subsequent anti-myeloma therapy at the entry of the study and at any time of during the study will be reported. |
Up to 15 years
|
|
Overall Survival (OS)
Délai: Up to 15 years
|
OS is measured from the date of randomization to the date of the participant's death. |
Up to 15 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies vasculaires
- Maladies cardiovasculaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies hématologiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Tumeurs, plasmocyte
- Troubles hémostatiques
- Paraprotéinémies
- Troubles des protéines sanguines
- Troubles hémorragiques
- Maladies hémiques et lymphatiques
- Myélome multiple
Autres numéros d'identification d'étude
- CR109123
- 2020-005521-84 (Numéro EudraCT)
- 68284528MMY4002 (Autre identifiant: Janssen Research & Development, LLC)
- 2023-505530-10-00 (Identificateur de registre: EUCT number)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .